SCHEMBL16692866

SCHEMBL16692866

Fc1ccc(CN2CCOc3cnc(Cl)nc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNIK Q9UKE5 3/20 0.44
▸ AURKA O14965 1/20 0.44
▸ FLT1 P17948 1/20 0.44
▸ GCK P35557 1/20 0.44
▸ FLT4 P35916 1/20 0.44
▸ MAP3K11 Q16584 1/20 0.44
▸ STK17A Q9UEE5 1/20 0.44
▸ DRD2 P14416 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ ABL1 P00519 1/20 0.37
▸ BCR P11274 1/20 0.37
▸ TSHR P16473 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ MAPT P10636 2/20 0.36
▸ NR1I2 O75469 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30443099 1.00 TNIK (0.44) TNIKAURKAFLT1GCKFLT4
SCHEMBL16692848 0.90 PKM (0.39) TNIKAURKAFLT1GCKFLT4
SCHEMBL16691340 0.87 GRM5 (0.41) TNIKALDH1A1MAPTMAPK1PKM
SCHEMBL16692826 0.86 TNIK (0.46) TNIKALDH1A1ABL1BCRSMN1; SMN2
SCHEMBL16692842 0.83 KCNH2 (0.43) DRD2DRD4DRD3ALDH1A1TSHR
SCHEMBL16692858 0.81 CYP2C9 (0.43) TNIKDRD2DRD3MAPTKCNH2
SCHEMBL16692874 0.79 ROCK2 (0.50) TNIKDRD2DRD3ALDH1A1KCNH2
SCHEMBL16691349 0.79 PSEN1 (0.47) DRD2DRD4DRD3ABL1BCR
SCHEMBL16692850 0.79 CYP2A13 (0.43) DRD2DRD3ALDH1A1POLBTSHR
SCHEMBL16691284 0.77 PSEN1 (0.45) TNIKABL1BCRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034133-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-01-30 — — US disclosed
WO-2023083297-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-19 — — WO disclosed
WO-2023083297-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-19 — — WO disclosed
WO-2015066697-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. (US) 2015-05-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034133-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 TNIK 726/4885AURKA 1813/4885FLT1 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback